TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18697848

Group type: EXPERIMENTAL
Intervention: Oral health counseling and dental exam at baseline, followed by randomization and follow-up visits at 9, 12, 18, 24, 30, and 36 months postpartum.
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Higher annual household income
Number of subjects: 556

Group type: EXPERIMENTAL
Intervention: Mexican/Mexican-American ethnicity
Number of subjects: 556
Study: 15668329

Group type: EXPERIMENTAL
Intervention: Adult open-bite patients
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Pre-pubertal open-bite patients
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 39
Study: 12836808

Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution
Number of subjects: 66

Group type: COMPARATOR
Intervention: Olopatadine hydrochloride 0.1% ophthalmic solution
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 66
Study: 10818329

Group type: EXPERIMENTAL
Intervention: Right internal jugular vein (RIJV) cannulation using the landmark approach (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Right internal jugular vein (RIJV) cannulation using surface ultrasound (Group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Left internal jugular vein (LIJV) cannulation using the landmark approach (Group 3)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Left internal jugular vein (LIJV) cannulation using surface ultrasound (Group 4)
Number of subjects: 120
Study: 8852909

Group type: EXPERIMENTAL
Intervention: PRP-T conjugate vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diphtheria-tetanus-pertussis vaccine
Number of subjects: 0
Study: 1906248

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Methohexitone
Number of subjects: 70
Study: 6872409

Group type: EXPERIMENTAL
Intervention: Propranolol (240 mg daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Metoprolol (300 mg daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29087035

Group type: EXPERIMENTAL
Intervention: Neurocognitive assessment battery (including Executive Function, Processing Speed, and Verbal Memory)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Processing Speed tests
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Executive Function tests
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Memory performance
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Declines in Executive Function
Number of subjects: 49
Study: 27922569

Group type: EXPERIMENTAL
Intervention: Paper cognitive aid (CA)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Electronic cognitive aid (CA)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control (memory alone)
Number of subjects: 139
Study: 25231808

Group type: EXPERIMENTAL
Intervention: Newborn care education (50-minute session using video, verbal education, demonstration and practice)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no education)
Number of subjects: 53
Study: 23557224

Group type: EXPERIMENTAL
Intervention: PRK + 0.02% mitomycin C (MMC) for 20 seconds
Number of subjects: 27

Group type: COMPARATOR
Intervention: PRK
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Total sample preoperative and postoperative results
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Corneal sensation
Number of subjects: 27
Study: 20863238

Group type: EXPERIMENTAL
Intervention: Efavirenz-based antiretroviral therapy
Number of subjects: 196
Study: 18936218

Group type: EXPERIMENTAL
Intervention: 200 mg/d AA + (n‐3) LCPUFA (320 mg/d DHA, 80 mg/d eicosapentaenoic acid, 80 mg/d other (n‐3) fatty acids)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 400 mg/d AA + (n‐3) LCPUFA (320 mg/d DHA, 80 mg/d eicosapentaenoic acid, 80 mg/d other (n‐3) fatty acids)
Number of subjects: 33

Group type: COMPARATOR
Intervention: (n‐3) LCPUFA alone (320 mg/d DHA, 80 mg/d eicosapentaenoic acid, 80 mg/d other (n‐3) fatty acids)
Number of subjects: 33
Study: 16827739

Group type: EXPERIMENTAL
Intervention: Randomization procedure reporting
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Blinding in outcome assessment
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Handling of subject withdrawals
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Overall quality scores
Number of subjects: 43
Study: 12756020

Group type: EXPERIMENTAL
Intervention: VAD combined with fludarabine (25 mg/m2/day i.v. for 5 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: VAD (control group)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: VAD combined with fludarabine
Number of subjects: 19
Study: 10963641

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF) adjuvant therapy
Number of subjects: 281

Group type: COMPARATOR
Intervention: No further treatment after surgery +/‐ radiotherapy (Control)
Number of subjects: 281
Study: 8797150

Group type: EXPERIMENTAL
Intervention: L-arginine 20 g/day
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: D-arginine 10 microM
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: L-arginine 10 microM
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 1508620

Group type: EXPERIMENTAL
Intervention: Stimulus duration of 50 msec with ISOIs of 20-50 msec
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Stimulus duration of 10 msec or less
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Various ISOIs (0, 2, 4, 6, 8, 10, 15, 20, 50, or 70 msec)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Duration x ISOI interaction
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Separation x duration x ISOI interaction
Number of subjects: 5
Study: 6234341

Group type: EXPERIMENTAL
Intervention: Group I - 5.25% NaOCl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group II - 17% EDTA followed by 5.25% NaOCl
Number of subjects: 0
Study: 30430961

Group type: EXPERIMENTAL
Intervention: Prediction model using data up to week 1
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Prediction model using data up to week 3
Number of subjects: 2011

Group type: EXPERIMENTAL
Intervention: Remission at week 9
Number of subjects: 2011
Study: 30547481

Group type: EXPERIMENTAL
Intervention: Self-management education programme
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Health literacy questionnaire
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Socio-anthropological perspective
Number of subjects: 40
Study: 26582396

Group type: EXPERIMENTAL
Intervention: H. pylori treatment (n=87)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo (n=82)
Number of subjects: 169
Study: 25093169

Group type: EXPERIMENTAL
Intervention: Intensified and modulated adjuvant treatment with a minimum dose of 64.8 Gy, higher doses of 70.2 Gy (85.4%), pelvic lymph nodes irradiation (57.7%), and/or hormonal therapy (69.1%)
Number of subjects: 123
Study: 22435948

Group type: EXPERIMENTAL
Intervention: Intensive therapy
Number of subjects: 621

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 621
Study: 21294424

Group type: EXPERIMENTAL
Intervention: Home rehabilitation program
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional hospital care
Number of subjects: 58
Study: 18005604

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Patellar reshaping
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 16186073

Group type: EXPERIMENTAL
Intervention: Oral hormone replacement therapy (HRT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Transdermal hormone replacement therapy (HRT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 14520226

Group type: EXPERIMENTAL
Intervention: Postprandial blood glucose monitoring
Number of subjects: 61

Group type: COMPARATOR
Intervention: Preprandial blood glucose monitoring
Number of subjects: 61
Study: 10652167

Group type: EXPERIMENTAL
Intervention: Eyecor Camera System
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard vision screening techniques
Number of subjects: 127
Study: 9074912

Group type: EXPERIMENTAL
Intervention: Bromocryptine
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lisuride
Number of subjects: 19
Study: 1916980

Group type: EXPERIMENTAL
Intervention: Intercapsular technique
Number of subjects: 76

Group type: COMPARATOR
Intervention: Endocapsular technique
Number of subjects: 76
Study: 6624767

Group type: EXPERIMENTAL
Intervention: Daily home glucose monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly venipuncture protocol
Number of subjects: 0
Study: 30621659

Group type: EXPERIMENTAL
Intervention: Calcium hydroxide cement associated with HVGIC
Number of subjects: 108

Group type: COMPARATOR
Intervention: HVGIC restoration
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 108
Study: 29264836

Group type: EXPERIMENTAL
Intervention: Vorinostat (VOR) 200 mg po alternating 7 days on then 7 days off throughout a 28-day cycle with Bevacizumab (BEV) 10 mg/kg iv every 2 weeks and daily Temozolomide (TMZ) 50 mg/m² po daily
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vorinostat (VOR) 400 mg po alternating 7 days on then 7 days off throughout a 28-day cycle with Bevacizumab (BEV) 10 mg/kg iv every 2 weeks and daily Temozolomide (TMZ) 50 mg/m² po daily
Number of subjects: 48
Study: 26519119

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined exercise prescription
Number of subjects: 60
Study: 25526360

Group type: EXPERIMENTAL
Intervention: Percutaneous kyphoplasty (PKP) with routine biopsy of every operated vertebral level (biopsy group)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP) without biopsy (control group)
Number of subjects: 196
Study: 22484341

Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral therapy for insomnia and osteoarthritis pain (CBT‐PI)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Group cognitive‐behavioral therapy for osteoarthritis pain alone (CBT‐P)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Education only control (EOC)
Number of subjects: 367
Study: 20849619

Group type: EXPERIMENTAL
Intervention: Care as usual with the addition of occupational therapy
Number of subjects: 117

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 117
Study: 17990475

Group type: EXPERIMENTAL
Intervention: Oral care via intermittent suction
Number of subjects: 36
Study: 15847101

Group type: EXPERIMENTAL
Intervention: Artrofoon (8 tablets daily, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diclofenac (100 mg daily, n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Artrofoon (4 tablets daily)
Number of subjects: 60
Study: 11887515

Group type: EXPERIMENTAL
Intervention: New toothbrush
Number of subjects: 0

Group type: COMPARATOR
Intervention: Worn toothbrush
Number of subjects: 0
Study: 9785074

Group type: EXPERIMENTAL
Intervention: Org 9487 1 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Org 9487 2 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Org 9487 3 mg kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Org 9487
Number of subjects: 0
Study: 7615614

Group type: EXPERIMENTAL
Intervention: Group I - Axial dynamisation (fixator unlocked at 4 to 6 weeks)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group II - Spring fixator (unlocked at 4 to 6 weeks with a small silicone spring)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group III - Spring fixator (unlocked from the start for cyclical micromovement)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Group I - Axial dynamisation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group II - Spring fixator
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Group III - Spring fixator with cyclical micromovement
Number of subjects: 56
Study: 2384819

Group type: EXPERIMENTAL
Intervention: Gated blood pool scintigraphy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inter-observer variability assessment
Number of subjects: 20
Study: 364364

Group type: EXPERIMENTAL
Intervention: Dipyridamole 225 mg/day and acetylsalicylic acid 1 gm/day
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Overall incidence
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 132
Study: 30615007

Group type: EXPERIMENTAL
Intervention: Momentary Failure (MF)
Number of subjects: 12
Study: 30983008

Group type: EXPERIMENTAL
Intervention: Induction chemoimmunotherapy
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplant (ASCT)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: BEAM conditioning regimen
Number of subjects: 228

Group type: COMPARATOR
Intervention: Busulfan and melphalan (BuMel) conditioning regimen
Number of subjects: 228
Study: 28083842

Group type: EXPERIMENTAL
Intervention: VPZ 20 mg once daily for 3 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LPZ 30 mg once daily for 3 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 25827645

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22888813

Group type: EXPERIMENTAL
Intervention: Parent instrumental social support
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: Parent emotional social support
Number of subjects: 1421

Group type: EXPERIMENTAL
Intervention: Self-efficacy (SE)
Number of subjects: 1421
Study: 22046271

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: House-dust mite avoidance
Number of subjects: 249
Study: 19445938

Group type: EXPERIMENTAL
Intervention: Insulin resistance measured by HOMA2-IR
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Presence of steatosis on baseline biopsy
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Presence of Mallory bodies
Number of subjects: 985

Group type: EXPERIMENTAL
Intervention: Significant weight change of >or=5% in the first year after randomization
Number of subjects: 985
Study: 16768836

Group type: EXPERIMENTAL
Intervention: 15 mg supplemental Zn per day
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 30 mg supplemental Zn per day
Number of subjects: 48

Group type: COMPARATOR
Intervention: 0 mg supplemental Zn per day (placebo)
Number of subjects: 48
Study: 14695850

Group type: EXPERIMENTAL
Intervention: Purine analogs alone or in combination with alkylating agents and monoclonal antibodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alkylating agent-based therapy
Number of subjects: 0
Study: 11323555

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg.kg‐1 of body mass)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9460568

Group type: EXPERIMENTAL
Intervention: Nurse Specialist Anticoagulant Service (NSAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consultant Anticoagulant Service (CAS)
Number of subjects: 0
Study: 7943793

Group type: EXPERIMENTAL
Intervention: Adenosine (70 micrograms.kg‐1.min‐1 i.v.)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Morphine (0.1 mg/kg i.v.)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ketamine (0.1 mg/kg i.v.)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Adenosine + Morphine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Adenosine + Ketamine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 3145269

Group type: EXPERIMENTAL
Intervention: Phenethicillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Co‐trimoxazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antimicrobial agents (general)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cefaclor, co‐trimoxazole, doxycycline
Number of subjects: 0
Study: 31980499

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonpregnant women with T2DM (Control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Metformin (both doses)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg and 1000 mg)
Number of subjects: 48
Study: 27883233

Group type: EXPERIMENTAL
Intervention: Intranasal insulin application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no application)
Number of subjects: 0
Study: 25953832

Group type: EXPERIMENTAL
Intervention: Intranasal scopolamine (0.4 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 24334216

Group type: EXPERIMENTAL
Intervention: Sexunzipped interactive intervention website
Number of subjects: 2036

Group type: COMPARATOR
Intervention: Information-only control website
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Higher value compensation (£20/US$32)
Number of subjects: 2036

Group type: EXPERIMENTAL
Intervention: Lower value compensation (£10/US$16)
Number of subjects: 2036
Study: 21317165

Group type: EXPERIMENTAL
Intervention: MP4OX
Number of subjects: 474

Group type: COMPARATOR
Intervention: HES (hydroxyethyl starch)
Number of subjects: 474
Study: 18835434

Group type: EXPERIMENTAL
Intervention: 10-week group-based cognitive behavioral stress management (CBSM) intervention
Number of subjects: 128

Group type: COMPARATOR
Intervention: 1-day psychoeducational control group
Number of subjects: 128
Study: 17145651

Group type: EXPERIMENTAL
Intervention: Combination of isoflavones, lignans and Cimicifuga racemosa (group A, n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Calcium supplements (group B, n = 40)
Number of subjects: 80
Study: 14718406

Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control patients (non-HIV)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: HIV-infected patients undergoing percutaneous coronary intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control patients undergoing percutaneous coronary intervention
Number of subjects: 68
Study: 11760165

Group type: EXPERIMENTAL
Intervention: Induction treatment (3 million units daily for the first 14 days, then 3 times per week)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard treatment (3 million units 3 times per week throughout)
Number of subjects: 31
Study: 9268221

Group type: EXPERIMENTAL
Intervention: Tiqueside (1, 2, and 3 g daily, b.i.d.)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Tiqueside (2 or 4 g/day, once daily)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 8359182

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 0.4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 0.8 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 12
Study: 3458681

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 10

Group type: COMPARATOR
Intervention: Gel alone
Number of subjects: 10
Study: 28846469

Group type: EXPERIMENTAL
Intervention: 12% SDF applied annually (every 12 months)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: 12% SDF applied semiannually (every 6 months)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: 38% SDF applied annually (every 12 months)
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: 38% SDF applied semiannually (every 6 months)
Number of subjects: 888

Group type: COMPARATOR
Intervention: 38% SDF
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Annual SDF application with higher VPI score
Number of subjects: 888
Study: 26374745

Group type: EXPERIMENTAL
Intervention: TT-173
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23434921

Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 21988715

Group type: EXPERIMENTAL
Intervention: Acetil salicylic acid (ASA) 100 mg daily until third month of pregnancy
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Low molecular-weight heparin (LMWH) - enoxaparine 40 mg daily until third month of pregnancy
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: ASA 100 mg plus LMWH 40 mg daily until third month of pregnancy
Number of subjects: 167

Group type: COMPARATOR
Intervention: ASA 100 mg daily until third month of pregnancy
Number of subjects: 167
Study: 19804570

Group type: EXPERIMENTAL
Intervention: SPO (Spectra Optia)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CSP (COBE Spectra)
Number of subjects: 20
Study: 17963864

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Laminaria
Number of subjects: 37
Study: 15905896

Group type: EXPERIMENTAL
Intervention: 50 min treadmill walk (50% VO(2) peak)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control days
Number of subjects: 18
Study: 12325052

Group type: EXPERIMENTAL
Intervention: Emotion-oriented care intervention
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 151
Study: 10776982

Group type: EXPERIMENTAL
Intervention: GRADEX (granisetron 3 mg i.v. + dexamethasone 20 mg i.v.)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: TRODEX (tropisetron 5 mg i.v. + dexamethasone 20 mg i.v.)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: ONDEX (ondansetron 8 mg i.v. + dexamethasone 20 mg i.v. followed by ondansetron 8 mg p.o. x 2)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: GRADEX (first cycle)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: TRODEX (first cycle)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: ONDEX (first cycle)
Number of subjects: 89

Group type: COMPARATOR
Intervention: GRADEX vs TRODEX
Number of subjects: 89
Study: 8733437

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 mg/week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (MTX and placebo)
Number of subjects: 40
Study: 1348986

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120